DDrare: Database of Drug Development for Rare Diseases

226. 間質性膀胱炎（ハンナ型）
［臨床試験数：133，薬物数：151（DrugBank：46），標的遺伝子数：48，標的パスウェイ数：137］

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04401176 (ClinicalTrials.gov)	July 2020	19/5/2020	Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A	Walter Reed National Military Medical Center	NULL	Not yet recruiting	18 Years	N/A	Female	58	Phase 2	NULL
2	NCT03463915 (ClinicalTrials.gov)	January 25, 2019	28/2/2018	Clinical Trial Comparing Two Bladder Instillations for IC/BPS	Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: Bladder instillation WITH triamcinolone acetonide;Drug: Bladder instillation WITHOUT triamcinolone acetonide	Olivia Cardenas-Trowers, M.D.	NULL	Completed	18 Years	N/A	Female	90	Phase 3	United States
3	NCT02870738 (ClinicalTrials.gov)	April 21, 2017	12/8/2016	Bladder Directed vs. Pelvic Floor Therapy in IC/BPS	Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome	Cystitis, Interstitial;Painful Bladder Syndrome	Procedure: Pelvic Floor Physical Therapy;Drug: Bladder Instillations	William Beaumont Hospitals	Baylor College of Medicine	Recruiting	18 Years	85 Years	Female	128	Phase 2	United States
4	EUCTR2015-004495-30-FI (EUCTR)	14/12/2015	20/10/2015	Safety of intravesical bladder instillations among patients with severe interstitial cystitis	Safety of intravesical bladder instillations among patients with severe interstitial cystitis	Interstitial cystitis and bladder pain syndrome MedDRA version: 18.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 18.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]	Trade Name: SANDIMMUN INN or Proposed INN: CICLOSPORIN	Oulu University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Finland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04401176
(ClinicalTrials.gov)

July 2020

19/5/2020

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis;Bladder Pain Syndrome

Drug: Heparin & Alkalinized Lidocaine Bladder Instillation;Drug: Onabotulinum Toxin A

Walter Reed National Military Medical Center

NULL

Not yet recruiting

18 Years

N/A

Female

Phase 2

NULL

NCT03463915
(ClinicalTrials.gov)

January 25, 2019

28/2/2018

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis;Bladder Pain Syndrome

Drug: Bladder instillation WITH triamcinolone acetonide;Drug: Bladder instillation WITHOUT triamcinolone acetonide

Olivia Cardenas-Trowers, M.D.

NULL

Completed

18 Years

N/A

Female

Phase 3

United States

NCT02870738
(ClinicalTrials.gov)

April 21, 2017

12/8/2016

Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome

Cystitis, Interstitial;Painful Bladder Syndrome

Procedure: Pelvic Floor Physical Therapy;Drug: Bladder Instillations

William Beaumont Hospitals

Baylor College of Medicine

Recruiting

18 Years

85 Years

Female

128

Phase 2

United States

EUCTR2015-004495-30-FI
(EUCTR)

14/12/2015

20/10/2015

Safety of intravesical bladder instillations among patients with severe interstitial cystitis

Interstitial cystitis and bladder pain syndrome
MedDRA version: 18.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 18.1;Level: PT;Classification code 10011796;Term: Cystitis interstitial;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]

Trade Name: SANDIMMUN
INN or Proposed INN: CICLOSPORIN

Oulu University Hospital

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Finland